Introduction
Killing of tumor cells by cytotoxic therapies, such as chemotherapy, g-irradiation or immunotherapy, is predominantly mediated by triggering apoptosis in cancer cells (Debatin, 1997 (Debatin, , 1999 Kaufmann and Earnshaw, 2000; Lowe and Lin 2000; Solary et al., 2000; Herr and Debatin 2001; Johnstone et al., 2002) . Apoptosis or programmed cell death is a distinct, intrinsic cell death program that occurs in various physiological and pathological situations (Hengartner, 2000) . The underlying mechanisms for initiation of an apoptosis response upon cytotoxic therapy may depend on the individual stimulus and have not exactly been identified. However, damage to DNA or to other critical molecules is considered to be a common initial event, which is then propagated by the cellular stress response (Rich et al., 2000; Johnstone et al., 2002) . Multiple stress-inducible molecules, for example, JNK, MAPK/ERK, NF-kB or ceramide have been implied in the regulation of apoptosis (Leppa and Bohmann, 1999; Davis, 2000; Karin et al., 2002) . Also, T or NK cells may contribute to tumor cell killing by releasing cytotoxic compounds such as granzyme B or by using 'death ligands', which directly activate downstream apoptosis mechanisms inside the cell (Hengartner, 2000) .
Apoptosis is characterized by typical morphological and biochemical changes including cell shrinkage, nuclear DNA fragmentation and membrane blebbing (Hengartner, 2000) . In classical apoptosis caspases act as key effector molecules (Kaufmann, 1989; Ashkenazi and Dixit, 1998; Thornberry and Lazebnik, 1998; Earnshaw et al., 1999; Los et al., 1999; Slee et al., 1999; Utz and Anderson, 2000) . Initiation of the apoptosis response leading to caspase activation may follow activation of the death receptor pathway (exogenous pathway) or the mitochondrial pathway (endogenous pathway). Although different molecules participate in the core machinery of both apoptosis signaling systems, crosstalk exists at multiple levels. Deregulated apoptosis with increased expression of antiapoptotic molecules of the Bcl-2 family or loss of proapoptotic molecules such as Bax, Apaf-1 or caspase-8 has been found in many tumors both in cell lines and in human tumors in vivo, and is suggested to contribute to tumorigenesis and malignant progression of transformed cells. Downregulation of death receptors and increased expression of death-inducing ligands (DIL) of the tumor necrosis factor (TNF) superfamily have been discussed in the context of tumor/host interaction.
The antiapoptotic mechanisms regulating cell death also have been implicated in conferring drug resistance to tumor cells (Reed, 1999; Igney and Krammer, 2002a, b; Kaufmann and Vaux, 2003) . However, since a consistent link between the ability of tumor cells to undergo apoptosis in vitro and their susceptibility to anticancer therapy in vivo has not always been observed, the concept that anticancer therapies primarily act by inducing apoptosis has also been challenged (Finkel, 1999) . Therefore, nonapoptotic modes of cell death such as necrosis or cellular senescence may also mediate the cell death response to cytotoxic therapy (Borner and Monney, 1999; Johnson, 2000; Leist and Jaattela, 2001; Roninson et al., 2001; Sperandio et al., 2001) . In addition to the potential role in tumor development and sensitivity or resistance to current tumor therapy, elements of the apoptosis signaling systems have been shown to provide promising targets for the development of novel anticancer agents (Hu and Kavanagh, 2003) . A better molecular understanding of the diverse modes of cell death in cancer therapy is expected to provide novel strategies targeting cell death resistance in cancer.
The core apoptotic machinery
In most cases, anticancer drug treatment eventually results in the activation of caspases, a family of cysteine proteases that act as common death effector molecules in various forms of cell death (Ashkenazi and Dixit, 1998; Thornberry and Lazebnik, 1998; Earnshaw et al., 1999; Los et al., 1999; Slee et al., 1999; Hengartner, 2000; Utz and Anderson, 2000) . In all, 11 human caspases with different substrate specificity have so far been identified, which are involved in apoptosis signaling and also in cytokine processing (Ashkenazi and Dixit, 1998; Thornberry and Lazebnik, 1998; Earnshaw et al., 1999; Los et al., 1999; Slee et al., 1999; Utz and Anderson, 2000) .
Caspases involved in apoptosis signaling are categorized into initiator and effector caspases, respectively (Ashkenazi and Dixit, 1998; Thornberry and Lazebnik, 1998; Earnshaw et al., 1999; Los et al., 1999; Slee et al., 1999; Utz and Anderson, 2000) . Initiator caspases transduce various signals into protease activity and are directly linked to death signaling complexes: caspase-8 or -10 via their death effector domain (DED) interact with adaptor proteins Fas-associated death domain (FADD) recruited and bound to activated death receptors to form a death-inducing signaling complex (DISCs), while caspase-9 is recruited to the apoptosome via its CARD domain (Thornberry and Lazebnik, 1998) . Effector caspases cleave various substrates in the cytoplasm or nucleus, resulting in many of the morphologic features of apoptotic cell death (Ashkenazi and Dixit, 1998; Thornberry and Lazebnik, 1998; Earnshaw et al., 1999; Los et al., 1999; Slee et al., 1999; Utz and Anderson, 2000) . For example, polynucleosomal DNA fragmentation is mediated by cleavage of ICAD (inhibitor of caspase-activated DNase), the inhibitor of the endonuclease CAD (caspaseactivated DNase) that cleaves DNA into the characteristic oligomeric fragments (Nagata, 2000) . Proteolysis of several cytoskeletal proteins such as actin or fodrin leads to loss of overall cell shape, while degradation of lamin results in nuclear shrinking (Hengartner, 2000) .
Activation of caspases principally occurs by two different mechanisms (Figure 1 ): according to the induced proximity model initiator caspases such as Figure 1 Apoptosis pathways in anticancer therapy. Apoptosis pathways can be triggered through different entry sites, for example, at the plasma membrane upon crosslinking of death receptors (receptor pathway) or at the mitochondria (mitochondrial pathway). Stimulation of death receptors of the TNF receptor superfamily (DIL-R) such as CD95 (APO-1/Fas) or TRAIL receptors by DIL results in receptor aggregation and recruitment of the adaptor molecule FADD and caspase-8 into a DISC. Caspase-8 becomes activated upon recruitment and initiates apoptosis by direct cleavage of downstream effector caspases. The mitochondrial pathway is initiated by the release of apoptogenic factors such as cytochrome c, or Smac from mitochondria into the cytosol. The release of cytochrome c into the cytosol triggers caspase-3 activation through the formation of the cytochrome c/Apaf-1/caspase-9-containing apoptosome complex. Smac promotes caspase activation through neutralizing the inhibitory effects to IAPs, while AIF causes DNA condensation. The receptor and the mitochondrial pathway can be interconnected at different levels, for example, through Bid, a BH3 domain-containing protein of the Bcl-2 family, which assumes cytochrome c-releasing activity upon cleavage by caspase-8. Activation of caspases is negatively regulated at the receptor level by FLIP, which block caspase-8 activation, at the mitochondria by Bcl-2 family proteins and by IAPs. AIF, released from mitochondria mediates caspase-independent large-scale DNA fragmentation after translocation to the nucleus caspase-8 or -9 are activated in a multimeric complex, for example, caspase-8 in the DISC and caspase-9 at the apoptosome. (Ashkenazi and Dixit, 1998; Bratton et al., 2000; Ferri and Kroemer, 2000; Hengartner, 2000; Krammer, 2000; Kroemer and Reed, 2000; van Loo et al., 2002; Walczak and Krammer, 2000; Adrain and Martin, 2001) . Alternatively, caspases are activated by catalytic processing of the zymogens at specific cleavage sites (Thornberry and Lazebnik, 1998) . Caspase activation can be initiated from two different 'entry sites', the plasma membrane upon ligation of death receptor (receptor pathway) or at the mitochondria (mitochondrial pathway) (Thornberry and Lazebnik, 1998; Bratton et al., 2000; Hengartner, 2000) . Stimulation of death receptors of the TNF receptor superfamily such as CD95 (APO-1/Fas) or TNF-related apoptosis-inducing ligand (TRAIL) receptors results in receptor aggregation and recruitment of the adaptor molecule FADD and caspase-8 (Ashkenazi and Dixit, 1998; Krammer, 2000; Walczak and Krammer, 2000) . Upon recruitment, caspase-8, becomes activated and initiates apoptosis by direct cleavage of downstream effector caspases . The mitochondrial pathway is initiated by the release of apoptogenic factors such as cytochrome c, Smac/Diablo, Omi/HtrA2, endonuclease G, caspase-2 or -9 from the mitochondrial intermembrane space (Du et al., 2000; Kroemer and Reed, 2000; Suzuki et al., 2000; Li et al., 2001a, b; van Loo et al., 2002; Fulda et al., 2002) . The release of cytochrome c into the cytosol triggers caspase-3 activation through the formation of the cytochrome c/Apaf-1/caspase-9-containing apoptosome complex, while Smac/Diablo and Omi/HtrA2 promote caspase activation through neutralizing the inhibitory effects to inhibitor of apoptosis proteins (IAPs). In addition, apoptosis-inducing factor (AIF) has been described to mediate caspaseindependent death and large-scale DNA fragmentation after release from mitochondria (Ferri and Kroemer, 2000) .
The death receptor family
Death receptors are members of the TNF receptor gene superfamily, which consists of more than 20 proteins with a broad range of biological functions including the regulation of cell death and survival, differentiation or immune regulation (Ashkenazi and Dixit, 1998; Krammer, 2000; Walczak and Krammer, 2000) . Members of the (TNF) receptor family share similar, cysteine-rich extracellular domains. In addition, death receptors are defined by a cytoplasmic domain of about 80 amino acids called 'death domain', which plays a crucial role in transmitting the death signal from the cell's surface to intracellular signaling pathways. The best-characterized death receptors comprise CD95 (APO-1/Fas), TNF receptor 1 (TNFRI), TRAIL-R1 and TRAIL-R2, while the role of DR3 (TRAMP/Apo-3/WSL-1/LARD) or DR6 has not exactly been defined. The p75 nerve growth factor receptor also harbors a death domain through which cell death can be induced.
The corresponding ligands of the TNF superfamily comprise death receptor ligands such as CD95 ligand, TNFa, lymphotoxin-a (the later two bind to TNFRI), TRAIL and TWEAK, a ligand for DR3 . With the exception of lymphotoxin-a, all ligands are type II transmembrane proteins, which also exist as soluble molecules after cleavage by metalloproteases present in the microenvironment. Death receptors are activated upon oligomerization in response to ligand binding.
The CD95 receptor/CD95 ligand system is a key signal pathway involved in the regulation of apoptosis in several different cell types . CD95, a 48 kDa type I transmembrane receptor, is expressed in activated lymphocytes, in a variety of tissues of lymphoid or nonlymphoid origin, as well as in tumor cells. CD95L, a 40 kDa type II transmembrane molecule, occurs in a membrane-bound and in a soluble form, generated through cleavage by metalloproteases. CD95L is produced by activated T cells and plays a crucial role in the regulation of the immune system by triggering autocrine suicide or paracrine death in neighboring lymphocytes or other target cells. Also, CD95L is constitutively expressed in several tissues and has been implied in immune privilege of certain organs such as the testis or the eye (Green and Ferguson, 2001) . Moreover, CD95L expression on cancer cells has been implicated in immune escape of tumors (Igney and Krammer, 2001) . By constitutive expression of death receptor ligands such as CD95L, tumors may adopt a killing mechanism from cytotoxic lymphocytes to delete the attacking antitumor T cells through the induction of apoptosis via CD95/ CD95L interaction (Igney and Krammer, 2001 ). However, this model of tumor counterattack has also been challenged, since no study has so far conclusively demonstrated that tumor counterattack is a relevant immune escape mechanism in vivo.
Links between the receptor and the mitochondrial pathway exist at different levels (Roy and Nicholson, 2000) . Upon death receptor triggering, activation of caspase-8 may result in cleavage of Bid, a Bcl-2 family protein with a BH3 domain only, which in turn translocates to mitochondria to release cytochrome c, thereby initiating a mitochondrial amplification loop (Roy and Nicholson, 2000) . In addition, cleavage of caspase-6 downstream of mitochondria may feed back to the receptor pathway by cleaving caspase-8 (Cowling and Downward, 2002) .
TRAIL/Apo-2L was identified based on its sequence homology to other members of the TNF superfamily (Wiley et al., 1995; Walczak and Krammer, 2000) . Similar to CD95L, TRAIL is a type II transmembrane protein, but can be proteolytically cleaved from the cell surface. TRAIL is constitutively expressed in a wide range of tissues. Interestingly, the TRAIL receptor system is rather complex. (LeBlanc and Ashkenazi, 2003) .
TRAIL-R1 and TRAIL-R2, the two agonistic TRAIL receptors, contain a conserved cytoplasmic death domain motif, which engages the apoptosis machinery upon ligand binding (Chaudhary et al., 1997; MacFarlane et al., 1997; Pan et al., 1997a, b; Walczak et al., 1997; Wu et al., 1997) .
TRAIL-R3 to TRAIL-R5 are antagonistic decoy receptors that bind TRAIL but do not transmit a death signal (Degli-Esposti et al., 1997a, b; Pan et al., 1997; LeBlanc and Ashkenazi, 2003) . TRAIL-R3 is a glycosylphosphatidylinositol GPI-anchored cell surface protein, which lacks a cytoplasmic tail, while TRAIL-R4 harbors a substantially truncated cytoplasmic death domain. In addition to these four membrane-associated receptors, osteoprotegerin is a soluble decoy receptor, which is involved in the regulation of osteoclastogenesis (Emery et al., 1998) .
Similar to CD95L, TRAIL rapidly triggers apoptosis in many tumor cells. Wajant et al., 2002; LeBlanc and Ashkenazi, 2003) . Ligation of the agonistic TRAIL receptors TRAIL-R1 and TRAIL-R2 by TRAIL or agonistic antibodies results in receptor trimerization and clustering of the receptors' death domains (Kischkel et al., 2000; Sprick et al., 2000; Walczak and Krammer, 2000; LeBlanc and Ashkenazi, 2003) , leading to the formation of a DISC similar to engagement of CD95. The death-inducing signaling complexes of both death receptors contain FADD and caspase-8. In addition to caspase-8, also caspase-10 is recruited to the TRAIL DISC. However, the importance of caspase-10 in the TRAIL DISC for apoptosis induction has been controversially discussed .
The TRAIL system has attracted considerable attention for cancer therapy since TRAIL has been shown to kill cancer cells predominantly, while sparing normal cells (see below). The underlying mechanisms for the differential sensitivity of malignant vs nonmalignant cells is not well understood. Screening of various different tumor cell types in normal cells did not reveal a consistent association between TRAIL sensitivity and expression of agonistic or antagonistic TRAIL receptors as suggested (Ozoren and El-Deiry, 2003) . Instead, susceptibility for TRAIL-induced cytotoxicity has been suggested to be regulated intracellularly.
Death receptor signaling in cancer therapy
The relative contribution of the receptor and the mitochondrial pathway to drug-induced apoptosis has been controversially discussed (Debatin, 1999; Kaufmann and Earnshaw, 2000; Herr and Debatin 2001; Kaufmann and Vaux, 2003) . Several studies demonstrated that apoptosis induced by anticancer therapy involves the CD95 system. Treatment with anticancer drugs led to an increase in CD95L expression, which triggered the receptor pathway in an autocrine or paracrine manner by binding to its receptor CD95 (Friesen et al., 1996 (Friesen et al., , 1997 (Friesen et al., , 1999 Fulda et al., 1997a Fulda et al., , b, 1998a Fulda et al., -c, 2000a Leverkus et al., 1997; Herr et al., 1997; Houghton et al., 1997; Muller et al., 1997 Muller et al., , 1998 Reap et al., 1997; Kasibhatla et al., 1998; Eichhorst et al., 2000 Eichhorst et al., , 2001 Mo and Beck, 1999) . In support of this concept, upregulation of CD95L was observed in many different tumor cell lines, for example, leukemia, neuroblastoma, malignant brain tumors, hepatoma, colon, breast or small lung cell carcinoma cells in vitro and also ex vivo in primary, patients' derived tumor cells. Various anticancer agents with different primary intracellular targets have been used in these studies including DNA-damaging agents such as doxorubicin, etoposide, cisplatin or bleomycin. The CD95 receptor/ ligand system has also been implicated in thymine-less death in colon carcinoma cells following treatment with 5-fluorouracil (5-FU) (Houghton et al., 1997) . Activation of the transcription factors AP-1 and NF-kB was shown to mediate the increase in CD95L transcription and mRNA levels in response to chemotherapy (Herr et al., 1997; Kasibhatla et al., 1998; Eichhorst et al., 2000) . AP-1 and NF-kB binding sites were identified in the human CD95L promotor, which respond to DNA damage or inhibition of DNA metabolism by upregulating NF-kB activity (Kasibhatla et al., 1998) . In addition to CD95L, CD95 expression on the cell's surface increased upon drug treatment, in particular, in cells harboring wild-type p53 (Fulda et al., 1998a-c; Muller et al., 1997 Muller et al., , 1998 . p53-responsive elements have been identified in the first intron of the CD95 gene, as well as three putative p53-binding sites within the CD95 promotor, which showed homology with the p53 consensus binding site (Muller et al., 1997 (Muller et al., , 1998 . Also, rapid transport of presynthesized CD95 receptor molecules stored in vesicles to the cell membrane upon activation of p53 may contribute to the upregulation of CD95 surface expression in response to chemotherapy (Beltinger et al., 1999) . Moreover, antagonistic CD95L antibodies, soluble antagonistic CD95 receptors or DN-FADD were found to reduce drug-induced apoptosis under certain circumstances (Friesen et al., 1996; Fulda et al., 1997a, b; Reap et al., 1997; Muller et al., 1998) . In addition to the upregulation of CD95L and CD95, anticancer agents have been reported to activate the CD95 pathway by modulating expression and recruitment of pro-or antiapoptotic components of the CD95 DISC to activated receptors (Fulda et al., 2000) . Upregulation of FADD and procaspase-8 was found upon treatment with doxorubicin, cisplatin or mitomycin C in colon carcinoma cells (Micheau et al., 1999a, b) . Also, increased recruitment of FADD and procaspase-8 to the CD95 receptor to form the CD95 DISC was observed in certain tumor cells upon drug treatment in a CD95L-dependent or -independent manner (Beltinger et al., 1999) . In T-cell receptor-positive leukemia cells, treatment with doxorubicin, similar to CD3 triggering, led to the induction of functionally active CD95L, which caused cell death via CD95/CD95L interaction in a paracrine manner (Friesen et al., 1996; Fulda et al., 2000) . These findings indicate that in cells with an inducible CD95 receptor/ligand system, drug-induced apoptosis may involve CD95L-initiated DISC formation and activation of downstream effector programs comparable to activation-induced cell death in T cells. Moreover, in vivo, 5-FU induced apoptosis in mouse thymocytes via activation of the CD95 system, since apoptosis was blocked by neutralizing CD95L antibodies or in lpr mice lacking a functional CD95 receptor (Eichhorst et al., 2001) . Also, activation of the receptor pathway through CD95 receptor oligomerization independent of CD95L has been reported by suicide gene therapy using the herpes simplex thymidine kinase system or by UV-irradiation (Rehemtulla et al., 1997; Beltinger et al., 1999) . Furthermore, resistance to CD95-triggered apoptosis has been associated with crossresistance to various anticancer agents in some leukemia and solid tumor cell lines (Friesen et al., 1997) . Together, these data indicate that cell death signaling upon physiological stimuli such as CD95 triggering and chemotherapy requires, at least in part, similar pathways.
Despite the reproducibility of these findings in different model systems, other reports challenged the model that death receptor signaling is involved in drug-mediated cell death (Eischen et al., 1997; Villunger et al., 1997a, b; Kataoka et al., 1998; Landowski et al., 1999; Glaser et al., 1999; Wesselborg et al., 1999) . To that end, antagonistic antibodies against CD95L or CD95 did not confer protection against apoptosis induced by cytotoxic drugs in other cell lines (Villunger et al., 1997a, b; Glaser et al., 1999; Wesselborg et al., 1999) . Enforced expression of FLIP, DN-FADD or the serpin crmA did not inhibit drug-induced apoptosis, although it inhibited caspase-8 activation (Villunger et al., 1997a, b; Kataoka et al., 1998; Glaser et al., 1999; Wesselborg et al., 1999) . Also, targeted disruption of genes involved in death receptor signaling conferred no protection against cytotoxic drug treatment, at least in nontransformed cells such as murine embryonic fibroblasts (MEF). FADD À/À and caspase-8
fibroblasts were sensitive to cytotoxic drugs, while they remained resistant to death receptor stimulation (Varfolomeev et al., 1998; Yeh et al., 1998) . In contrast, caspase-9 À/À embryonic stem cells and Apaf-1 À/À thymocytes were sensitive to death receptor triggering, however, remained resistant to cytotoxic drugs Yoshida et al., 1998) . However, sensitivity of Apaf-1 À/À MEFs has also been described (Marsden et al., 2002) .
The discrepancies in findings may be related to the relative contribution of the death receptor vs the mitochondrial pathway to drug-induced apoptosis, depending on the anticancer agent, dose and kinetics or on cell type-specific differences. For CD95 signaling, two different cell types have been identified (Scaffidi et al., 1998) . In type I cells, CD95 crosslinking triggers apoptosis independent of mitochondria. In these cells, blockade of the mitochondrial pathway by overexpression of Bcl-2 does not protect against CD95-induced apoptosis, since caspase-8 is already efficiently activated at the DISC upstream of mitochondria. In contrast, type II cells depend on the mitochondrial pathway for full activation of effector caspases, since only little caspase-8 is recruited and activated at the DISC. A similar cell type-dependent signaling has also been described following treatment with cytotoxic drugs (Fulda et al., 2000; Algeciras-Schimnich et al., 2003) . In type I cells, both the receptor and the mitochondrial pathway were activated upon drug treatment, since blockade of either the receptor pathway by overexpression of dominantnegative FADD (FADD-DN) or of the mitochondrial pathway by overexpression of Bcl-X L only partially inhibited apoptosis. In contrast, in type II cells, apoptosis was predominantly controlled by mitochondria, since overexpression of Bcl-2 completely blocked drug-induced apoptosis, while overexpression of FADD-DN had no protective effect.
The lack of efficacy of CD95/CD95L neutralizing agents in some instances may also be due to inaccessibility of their targets. Experiments with adenoviral delivery of a CD95L-GFP construct showed that CD95 and CD95L are stored intracellularly and colocalize to the Golgi apparatus and/or endoplasmatic reticulum (Hyer et al., 2000) . An anti-CD95 blocking antibody did not inhibit CD95L-induced cell death, suggesting that CD95L may trigger CD95 within the same intracellular compartment and that these two molecules may already interact prior to surface presentation. Some of the studies that challenge an involvement of the CD95 system in chemotherapy of tumor cells are based on experiments performed in E1A-transformed murine embryonic fibroblasts, but not in cancer cells. However, the mechanisms regulating apoptosis in nonmalignant cells may vary considerably from those in malignant tumor cells, which is highlighted by the differential sensitivity of these cell types to various death stimuli.
Although a considerable amount of data support a role of the CD95 system in anticancer drug-induced apoptosis, at least under certain circumstances, most cytotoxic drugs are considered to initiate cell death primarily by triggering a cytochrome c/Apaf-1/caspase-9-dependent pathway linked to mitochondria (Kaufmann and Vaux, 2003) . Collectively, these data point to a key role of the mitochondrial pathway in drug-induced apoptosis, while the CD95 system may amplify druginduced apoptosis under certain conditions. However, this amplification of the chemoresponse may have important clinical implications, since it may critically affect the time required for execution of the death program (Tang et al., 2000) . The concept of the mitochondrial pathway, being the central initiator to integrate stress stimuli into an apoptotic response with subsequent caspase activation, has also been challenged by showing that a functional apoptosome is dispensable for stress-induced apoptosis (Lassus et al., 2002; Marsden et al., 2002) . For example, activation of caspase-2 in response to cellular stress was found to be required for mitochondrial permeabilization rather than vice versa (Lassus et al., 2002) . In addition, Bcl-2 was reported to regulate a caspase activation program independent of the cytochrome c/caspase-9/Apaf-1-containing apoptosome (Marsden et al., 2002) . These studies suggest that mitochondria may act as amplifiers, but not initiators of cell death in stress-induced apoptosis.
CD95 system and tumor counter attack
Given the role of the CD95 system as one mediator of the cytotoxic activity of cells of the immune system such as T cells, the finding of downregulated CD95 expression on tumor cells concomitant with increased expres-sion of CD95L in the same cell has stimulated a concept called tumor counter attack (Bellgrau et al., 1995; Griffith et al., 1995; Strand et al., 1996; Villunger and Strasser, 1999; Igney et al., 2000; Green and Ferguson, 2001; Restifo, 2001; French and Tschopp, 2002; Igney and Krammer, 2002a, b) . According to this concept, immune cells would be unable to destroy tumor cells since they are attacked by the death ligand-expressing tumor cells. This concept was based on findings that CD95L is expressed in immune privileged sites such as the anterior chamber of the eye and the testis, and supported by transplantation experiments showing that corneal transplants are accepted without tissue matching or immunosuppressive therapy and the acceptance of allografts in the eye and the testis in human systems using mice with nonfunctional CD95L (gld). These findings suggested that CD95L acts to render a transplanted tissue an immune privileged site. However, transplantation experiments, for example, with Langerhans islets grafts have produced conflicting results (Lau et al., 1996; Allison et al., 1997; Kang et al., 1997a, b) . In the tumor setting, a number of studies have suggested that CD95-resistant tumors that express CD95L constitutively or after induction by chemotherapy may mediate a tumor counter attack leading to immune escape of the respective tumor (Igney et al., 2000; Restifo, 2001) . In experimental systems such tumor cells killed CD95-positive apoptosis-sensitive cells such as T cells in vitro. Also, experiments using mice deficient for CD95L (gld) or CD95 (lpr) showed that growth of CD95L-transfected tumors was significantly better compared to nontransduced cells in human tumors. Furthermore, apoptosis of tumor infiltrating lymphocytes has been found in situ within the CD95L-expressing tumor tissue (Hahne et al., 1996; O'Connell et al., 1996; Strand et al., 1996; Villunger et al., 1997a, b; Bennett et al., 1998) . However, experimental evidence has also been provided that CD95L expression by grafts or tumor cells targeted the cells for rapid destruction by infiltrating neutrophils (Allison et al., 1997; Arai et al., 1997; Kang et al., 1997a, b; Behrens et al., 2001) . So far, no study has conclusively demonstrated that the CD95L-expressing tumor cells specifically delete antitumor-specific lymphocytes and thereby escape the immune response leading to a growth advantage in vivo (Igney et al., 2000; Behrens et al., 2001) . The controversy on CD95/CD95L being involved in a tumor counter attack manner in the elimination of immune cells mediating an antitumor response is not entirely settled. According to the current experimental evidence, this mechanism appears to play a minor role in the progression of tumor cells by evading immune-mediated host control mechanisms.
Apoptosis resistance through defective death receptor signaling
Based on the concept that cytotoxic therapies primarily act by triggering apoptosis in cancer cells, defects in apoptosis programs may result in drug resistance. Signal transduction to cell death can principally be blocked by an increase in the amount of antiapoptotic molecules involved in the regulation of apoptosis or by downregulation of proapoptotic molecules. Sensitivity to anticancer therapy can be regulated at various levels along the signaling pathways.
Death receptors
Death receptor expression may vary between different cell types and can be downregulated or absent in resistant tumor cells, which has been assumed to contribute to immune escape of tumor cells from negative growth control (Debatin, 1997; Friesen et al., 1997; Elnemri et al., 2001; Igney and Krammer, 2002a, b; Kaufmann and Vaux, 2003) . Drug-resistant leukemia or neuroblastoma cells showed strong downregulation of CD95 expression, suggesting that critical levels of CD95 expression may have an impact on drug sensitivity (Friesen et al., 1997; Fulda et al., 1997a Fulda et al., , b, 1998a . Also, drug-resistant tumor cells were found to be deficient in the upregulation of CD95L in response to treatment with cytotoxic drugs that was involved in drug response in chemosensitive tumor cells (Friesen et al., 1997) . In line with a role as a putative tumor suppressor, heterozygous mutations of the CD95 gene located on chromosome 10q23 have been found in a considerable proportion of human tumors (Beltinger et al., 1998; Gronbaek et al., 1998; Lee et al., 2000; Landowski et al., 2001; Park et al., 2001a, b; Takakawa et al., 2001; Takayama et al., 2002; Muschen et al., 2002) . Also, loss of expression of TRAIL receptors I and II, both localized on chromosome 8p, has been found in several tumors through the loss of heterozygosity or epigenetic events such as promoter hypermethylation (Pai et al., 1998; Shin et al., 2001; van Noesel et al., 2002) .
Signaling through death receptors can also be negatively regulated by proteins that associate with their cytoplasmatic domains, for example, SODD, or by proteins such as FLIP that prevent the interaction between the adaptor molecule FADD and procaspase-8 (Tschopp et al., 1998; French and Tschopp, 1999; Jiang et al., 1999; Fulda et al., 2000; Kinoshita et al., 2000; Igney and Krammer, 2002a, b; Kaufmann and Vaux, 2003) . High FLIP expression that has been found in many tumor cells has been correlated with resistance to CD95-and TRAIL-induced apoptosis (Tschopp et al., 1998; French and Tschopp, 1999) . In addition, FLIP expression was associated with tumor escape from T-cell immunity and enhanced tumor progression in experimental studies in vivo pointing to a role of FLIP as a tumor progression factor (French and Tschopp, 1999) . However, the impact of FLIP on apoptosis sensitivity towards cytotoxic drugs may vary between cell types. Thus, overexpression of FLIP did not confer protection against cytotoxic drugs in T-cell leukemia cells, while FLIP antisense oligonucleotides or downregulation of FLIP expression by metabolic inhibitors such as actinomycin D sensitized various tumor cells for death receptor-induced apoptosis (Fulda et al., 2000; Kinoshita et al., 2000) .
Caspases
Given the important role of caspases as effector molecules of apoptosis inhibition of caspase activation may be an important factor in resistance. Conversely, restoration of a functional caspase system may be crucial to overcome resistance to death receptor triggering or cytotoxic treatment. Despite the central role of caspases for cell death execution, screening for mutations in initiator or executioner caspases in a variety of human tumors have at least initially detected caspase mutations as a rare event in human tumors (Mandruzzato et al., 1997) . Instead, caspase expression and function appears to be frequently impaired by epigenetic mechanisms in cancer cells (Baylin and Bestor, 2002) . Caspase-8 expression was found to be inactivated by hypermethylation of regulatory sequences of the caspase-8 gene in a number of different tumor cells derived from neuroblastoma, malignant brain tumors, Ewing tumor and small lung cell carcinoma both in cell lines in vitro and also in vivo in primary tumor samples (Teitz et al., 2000; Fulda et al., 2001; Baylin and Bestor, 2002) . Importantly, restoration of caspase-8 expression by gene transfer or by demethylation treatment-sensitized resistant tumor cells for death receptor-or drug-induced apoptosis.
Expression levels of individual caspases may have an impact on their overall activity (Janicke et al., 1998; Yang et al., 2001) . For example, MCF-7 breast carcinoma cells completely lack caspase-3 expression due to a frameshift mutation within exon 3 of the caspase-3 gene (Janicke et al., 1998) . These cells can be sensitized by transfection of procaspase-3 towards treatment with cytotoxic drugs (Yang et al., 2001) . Alternative splicing has been identified as another level of transcriptional regulation of caspase expression (Wang et al., 1994; Srinivasula et al., 1999) . The genes encoding procaspase-2 or -9 can generate short isoforms that prevent apoptosis in a dominant-negative manner. Conversely, enhanced transcription of caspase genes in response to cytotoxic treatment or cytokines may increase expression levels. Thus, treatment with IFNg resulted in enhanced expression of caspase proteins mediated by direct activation of STAT-1, a downstream transcription factor involved in IFNg signaling . Moreover, transcriptional upregulation of caspase-3 or -8 was reported upon drug treatment independent of STAT1 (Micheau et al., 1999) . In addition, subcellular compartmentalization of caspases may regulate their activation. Thus, in addition to their cytoplasmic localization, several caspases including caspase-2, -3 and -9 are found inside mitochondria (Budihardjo et al., 1999; Samali et al., 1999; Susin et al., 1999) . Death signals targeting mitochondria trigger the translocation of caspases from the mitochondrial intermembrane space into the cytosol and also promote their nuclear translocation.
IAPs
The family of endogenous caspase inhibitors, IAPs, are highly conserved throughout evolution and comprise the human analogues XIAP, cIAP1, cIAP2, survivin and livin (ML-IAP) (Altieri, 2001; Holcik and Korneluk, 2001; Salvesen and Duckett, 2002) . IAPs have been reported to inhibit directly active caspase-3 and -7 and to block caspase-9 activation (Altieri, 2001; Holcik and Korneluk, 2001; Salvesen and Duckett, 2002) . In addition to the regulation of apoptosis, IAP members such as survivin have been found to be involved in the regulation of mitosis (Altieri, 2001 ). Inhibition of apoptosis by IAPs in response to cytotoxic therapy has been suggested by several experimental studies to be an important mechanism of resistance (Adida et al., 1998 (Adida et al., , 2000 Datta et al., 2000; Tamm et al., 2000; Li et al., 2001a, b) . XIAP, cIAP1 or cIAP2 suppressed apoptosis in vitro following treatment with cisplatin, cytarabine, TRAIL, staurosporine or g-irradiation.
NF-kB
The transcription factor NF-kB has been connected with multiple aspects of oncogenesis, including cell proliferation or inhibition of apoptosis (Karin et al., 2002; Hu and Kavanagh, 2003) . NF-kB is composed of hetero-or homodimers of NF-kB/Rel family proteins, which mediate protein dimerization, nuclear import and specific DNA binding. In most cell types, NF-kB is sequestered in the cytoplasm by its interaction with IkB proteins and therefore remains inactive. Upon stimulation, IkB becomes phosphorylated following activation of the IKK complex and is degraded via the proteasome, thereby releasing NF-kB to translocate into the nucleus for transcription of target genes. NF-kB target genes include several antiapoptotic proteins, for example, cIAP1, cIAP2, TRAF1, TRAF2, Bfl-1/A1, Bcl-X L and FLIP. Interestingly, promotor activation of proapoptotic molecules of the TRAIL system including TRAIL-R1, TRAIL-R2 or TRAIL is also controlled by NF-kB consistent with reports that NF-kB can promote apoptosis under certain circumstances (Ravi et al., 2001) . NF-kB is constitutively active in tumor types such as Hodgkin's lymphoma or pancreatic carcinoma (Karin et al., 2002) . Also, NF-kB activity is induced in response to a variety of stimuli, for example, in response to cellular stress or anticancer agents. In addition, TRAIL itself has been reported to activate NF-kB, which is mediated by TRAIL-R1, TRAIL-R2 or TRAIL-R4 through a TRAF2-NIK-IKKa/b-dependent signaling cascade under conditions, when apoptosis is blocked (Chaudhary et al., 1997; Schneider et al., 1997; Harper et al., 2001; Erhardt et al., 2003) . Inhibition of NF-kB signaling by proteasome inhibitors, which prevent IkBa degradation, or by overexpression of nondegradable IkBa mutants, has been reported to sensitize tumor cells for TRAIL-induced apoptosis (Jeremias et al., 1998) .
Prognostic significance of apoptosis regulators
Most studies investigating the activation of apoptosis pathways by anticancer therapy have been performed in vitro. Despite many limitations of cell culture experiments, in vitro studies may in fact reflect some (but not all) of the important features of tumor treatment in vivo. For example, caspase activity was detected in leukemia and lymphoma cells during treatment in vivo (Kaufmann and Earnshaw, 2000; Stahnke et al., 2001 Stahnke et al., , 2003 Kaufmann and Vaux, 2003) . Based on the concept that the integrity of apoptosis pathways may be crucial for prognosis in cancer, a number of clinical studies have been performed to address the significance of expression of apoptosis regulators for treatment response and outcome (Schriever and Dorken, 2001; Kaufmann and Vaux, 2003) . In particular, the initial observation of a strong increase in Bcl-2 expression in chronic forms of indolent lymphomas (follicular lymphoma) and the function of Bcl-2 in apoptosis resistance and resistance to cancer therapy has stimulated studies addressing the role of Bcl-2 family proteins (Miyashita and Reed, 1993; Reed, 1996; Yang and Korsmeyer, 1996) . In this context, however, it is important to emphasize that mutations or alterations in apoptosis regulators may not lead to a 'yes or no' phenotype, but may rather modulate the cytotoxicity of current anticancer treatment. Therefore, recommendation for treatment based on such studies has to be given carefully. For example, the finding that p53 À/À thymocytes or p53 À/À experimental tumors are relatively resistant to many forms of damaging therapy including irradiation has led to the assumption that p53 tumors may be resistant to chemoradiotherapy in general (Lowe et al., 1994; Lowe, 1995; Finkel, 1999) . Clinical and experimental evidence, however, suggests that this is not always the case, although threshold levels of cell death in response to damaging therapy may be lifted and apoptosis delayed (Finkel, 1999) .
Most of the clinical and preclinical studies have tried to incorporate expression of apoptosis regulators, in particular, Bcl-2 and Bax in cancer patients into multiparameter analyses for prognosis and/or treatment response. Consequently, short-and long-term studies have been performed in a wide range of tumor entities including leukemia (Campos et al., 1993 (Campos et al., , 1996 (Campos et al., , 1999 Gala et al., 1994; Maung et al., 1994; Coustan-Smith et al., 1996; Min et al., 1996a, b; Robertson et al., 1996; Iijima et al., 1997; Lauria et al., 1997; Estrov et al., 1998; Tsurusawa et al., 1998; Hogarth and Hall, 1999; Wuchter et al., 1999a Wuchter et al., , b, 2000 Ong et al., 2000; Parker et al., 2000; Prokop et al., 2000; Svingen et al., 2000; Baghdassarian et al., 2001; Boudard et al., 2002; Kohler et al., 2002; Del Poeta et al., 2003; Schimmer et al., 2003) , lymphoma (Pezzella et al., 1992; Piris et al., 1994; Whang-Peng et al., 1995; Hermine et al., 1996; Hill et al., 1996; Gascoyne et al., 1997a,b; Wendum et al., 1997; Lopez-Guillermo et al., 1999; Rassidakis et al., 2002; ten Berge et al., 2002; Colomo et al., 2003; Vassallo et al., 2003) , breast cancer (Bargou et al., 1995; Kapranos et al., 1997; Krajewski et al., 1995a Krajewski et al., , b, 1997 Krajewski et al., , 1999 Sjostrom et al., 1998; Veronese et al., 1998; Rochaix et al., 1999; Kymionis et al., 2001; Sjostrom et al., 2002) , gastrointestinal cancers (Nakata et al., 1998; Yamamoto et al., 1999; Giatromanolaki et al., 2001; Satomi et al., 2002; Samowitz et al., 2002) and lung cancer (Apolinario et al., 1997; Chen et al., 1999; Gessner et al., 2002) and some pediatric tumors (Krajewski et al., 1995a, b) . In general, the expression of apoptosis regulators was analysed by PCR, immunocytochemistry or Western blot, and correlated to treatment response or outcome.
Interestingly, a number of studies in diverse tumors have at least initially confirmed the role of Bcl-2 family members in apoptosis resistance, treatment response and/or outcome. According to in vitro data as well as experimental data, one would expect that tumors that express high levels of Bcl-2 would be more aggressive and less responsive to treatment, while tumors expressing high levels of Bax would show a higher tendency to undergo apoptosis either spontaneously or even more so when induced by therapeutic agents. However, the clinical situation appears to be much more complex. In lymphoma, the classical area of discovery of Bcl-2 as a special type of proto-oncogene, there is clear evidence that the high levels of Bcl-2 at least in subgroups of tumors are associated with poor prognosis or resistance to treatment (Gascoyne et al., 1997a; Lopez-Guillermo et al., 1999) . However, in the absence of t14;18, levels of Bcl-2 expression may reflect the stage of maturation of the transformed normal counterpart of the malignant cell in lymphoma. There, long-term studies have shown a prognostic impact of Bcl-2 family members (Gascoyne et al., 1997b; Lopez-Guillermo et al., 1999; ten Berge et al., 2002) or alternatively have shown a complex pattern with no clear indication that Bcl-2 or Bax expression may be related to poor prognosis (Wendum et al., 1997; Vassallo et al., 2003) . In some cases, even prolonged survival in correlation to high Bcl-2 expression has been found.
Another example for studies that initially have shown a clear correlation that turned out later to be more complex are long-term studies in breast cancer. Several groups initially described independently that Bax expression is positively correlated with prognosis in this tumor entity (Bargou et al., 1995; Krajewski et al., 1995a, b) . This has been assigned to the apoptosisfacilitating role of Bax in neoadjuvant treatment strategies used in most breast cancer patients. However, several recently published long-term studies have provided entirely conflicting results showing a correlation of Bax with good prognosis, or no correlation or even a negative correlation, that is, Bax expression correlates to poor prognosis (Sjostrom et al., 1998 (Sjostrom et al., , 2002 Veronese et al., 1998; Krajewski et al., 1999; Kymionis et al., 2001) . One reason for this discrepancy may lay in the fact that levels of apoptosis regulators may fluctuate with differentiation and cycling of cells. Thus, high Bax levels could indicate clonal progression of tumor cells to a more malignant phenotype (Rochaix et al., 1999; Vakkala et al., 1999; Ionov et al., 2000) . Alternatively, disabling of Bax function by mutations may not reflect malignant progression but may rather reflect an intrinsic mutator phenotype of the tumor cells as identified in colorectal carcinoma (Rampino et al., 1997; Yamamoto et al., 1999) .
Analysis of genes involved in death receptor pathways has identified a significant percentage of mutations of these genes in hematological malignancies and solid tumors (Gala et al., 1994; Min et al., 1996; Beltinger et al., 1998; Gronbaek et al., 1998; Plumas et al., 1998; Lee et al., 2000; Landowski et al., 2001; Park et al., 2001a, b; Poulaki et al., 2001; Takakawa et al., 2001; Takayama et al., 2002; Muschen et al., 2002; Shin et al., 2002) . The incidence of CD95 mutations found in human tumors has been taken as evidence that the CD95 system exerts a tumor suppressor function. Increased serum levels of soluble CD95 generated by alternative mRNA splicing products were found in adult T-cell leukemia and were associated with reduced survival and outcome (Kamihira et al., 1999) . Also, CD95 expression has been positively correlated to response to therapy in AML (Min et al., 1996; Iijima et al., 1997) . In addition to CD95 mutations in TRAIL receptors and downstream elements of death receptor signaling also have recently been found in several tumors including lymphoma, non-small-cell lung cancer, gastric cancer and breast cancer (Pai et al., 1998; Lee et al., 2001a, b; Park et al., 2001a Park et al., , b, 2002 Shin et al., 2001 Shin et al., , 2002a van Noesel et al., 2002) . These studies also led to the discovery of a so far undescribed decoy receptor for CD95 ligand in lung and colon cancer (Pitti et al., 1998) .
Elevated FLIP expression counteracting apoptosis signaling through death receptors has been found in clinical samples from Burkitt lymphoma, pancreatic carcinoma, melanoma or neuroblastoma, and in tumor cells that developed resistance upon chemotherapy, suggesting that FLIP may play a role in chemoresistance of tumors (Tepper and Seldin, 1999) . Increased expression of IAPs correlated with poor treatment response in myeloid leukemia cells and elevated survivin expression predicted adverse prognosis in neuroblastoma, AML, colon, lung and esophagus carcinoma (Adida et al., 1998 (Adida et al., , 2000 Li et al., 2001a, b; Tamm et al., 2000) .
Given the complex regulation of apoptosis signaling in response to physiological signals or anticancer treatment, it is not surprising that analysis of individual molecules or even molecules of the same family of proteins cannot reflect the complexity of the signal pathways involved or the crosstalk of apoptosis signaling with other systems such as the DNA damage/repair response or cell cycle control. Therefore, a number of recent studies have incorporated the analysis of the expression of p53 status and cell cycle-regulating proteins into the analysis of apoptosis regulators with respect to prognosis and treatment outcome. However, also in these studies, the emerging picture is rather complex and apoptosis regulators did not emerge as single univariate parameters. As an example, a previous long-term study in colorectal carcinoma has identified p53 expression and Bax expression levels or Bax mutation as being not indicative for prognosis following combined radiochemotherapy (Rau et al., 2003) . This is in contrast to data by the same group showing low Bax expression and p53 status as a negative prognostic factor in colorectal cancer and esophageal carcinoma (Sturm et al., 1999 (Sturm et al., , 2001 Schelwies et al., 2002; Mro´zek et al., 2003) . The major difference between the study showing a lack of correlation of Bax/p53 with outcome in contrast to the other studies was the fact that the authors investigated post-treatment alterations in relation to the pretreatment status rather than the static pretreatment profile. Instead of an impact of the pretherapeutic status of p53 and Bax on outcome, they identified downregulation of p21 post-therapy, indicating diminished proliferation of tumor cells as a poor prognostic parameter in their study.
For two key apoptosis-regulating systems, the Bcl-2 family proteins and the CD95 death receptor system, a critical role for homeostasis in hematopoietic cells has been found through the discovery of these systems and experimental and genetic analysis in mice. Thus, it is not surprising that most of the studies on the impact of apoptosis signaling molecules have been performed in hematopoietic malignancies. For acute and chronic leukemia, some studies have identified a prognostic role for Bcl-2, CD95 expression, Bax expression and caspase expression or activation with respect to prognosis and treatment outcome, while other studies could not confirm such correlations (Table 1) . Historically, it is interesting that publications, which indicate a clear positive correlation between expression and prognosis (as expected from in vitro studies), were usually published first.
Also, none of the recent published studies on gene expression profiling in relation to treatment response and outcome has identified apoptosis regulators as key prognostic factors (Rosenwald et al., 2002; Cheok et al., 2003; Golub, 2003) . However, the limitations of these studies are obviously their lack of analysis of protein expression as well as the general inability of static 'snap shot assays' to detect functional activation of pathways in apoptosis signaling. The initiation or effector phase of apoptosis is only partially regulated at the level of protein expression, but rather by protein/protein interaction. In this respect, assay that address cell death signaling directly ex vivo or in vivo may further help to identify the prognostic impact of apoptosis regulators for rational therapy.
Therapeutic attempts to target the cell death machinery
Although successful tumor therapy in vivo may involve mechanisms of cell death induction other than classical apoptosis, apoptosis signaling molecules provide rational targets for the development of novel anticancer treatment strategies. Most studies in experimental systems in vitro and in vivo have highlighted the mitochondrial pathway as a key determinator of cell death in response to conventional treatment using cytotoxic drugs or irradiation. Some anticancer drugs may target preferentially mitochondria leading to the disturbance of the mitochondrial function and release of mitochondrial apoptogenic factors (Fulda et al., 1997a, b; Debatin et al., 2002) . Rather than targeting complex systems, current development of novel antic-ancer agents in the apoptosis field is directed at individual molecules of the cell death signaling machinery shown to act at key positions for cell death control. This includes death receptors, apoptosis blockers such as proteins of the IAP family and already fairly advanced strategies to overcome Bcl-2-mediated inhibition of physiological or therapeutical cell death signaling in cancer cells.
Targeting death receptors
TNFa has a long history of entering cancer treatment in clinical trials with the aim to induce cell death ( ¼ tumor necrosis) in tumors. Given the strong apoptosis-inducing effect of CD95 triggering in some tumors, also CD95 agonists were at least initially expected to provide novel therapeutic options. However, the lethal effects of CD95L agonistic antibodies in experimental systems leading to hypertension, liver failure and death prevented the systemic use of this potent apoptosis inducer as an antitumor drug. In addition to its toxic effects, the mostly disappointing clinical effectivity of TNF also largely removed this cytokine from the repertoire of anticancer regimens. Despite this disappointment, the idea to target specifically death receptors to trigger apoptosis in tumor cells is also attractive because death receptor engagement and subsequent cell death occurs independent of the p53 tumor suppressor gene, which is deleted or inactivated in more than half of human tumors (El-Deiry, 2001) .
In contrast to TNF and CD95L, TRAIL appears to be a relatively safe and promising candidate for clinical application, particularly in its nontagged, zinc-bound homotrimeric form. Studies in nonhuman primates such as chimpanzees and cynomolgous monkeys showed no toxicity upon intravenous infusion, even at high doses (Ashkenazi et al., 1999) . In addition, no cytotoxic activity of TRAIL was reported on a variety of normal human cells of different lineages including fibroblasts, endothelial cells, smooth muscle cells, epithelial cells or astrocytes. However, some concerns about potential toxic side effects on human hepatocytes or brain tissue have also been raised (Jo et al., 2000; Nitsch et al., 2000; Lawrence et al., 2001) . The loss of tumor selectivity may be related to the TRAIL preparations used in these studies. TRAIL preparations, which are antibody crosslinked or not optimized for Zn content, have been reported to form multimeric aggregates, thereby overcoming the threshold of sensitivity of normal cells (LeBlanc and Ashkenazi, 2003) .
Recombinant soluble TRAIL induced apoptosis in a broad spectrum of cancer cell lines, including colon carcinoma, breast carcinoma, lung carcinoma, pancreas carcinoma, prostate carcinoma, renal carcinoma, thyroid carcinoma, malignant brain tumors, Ewing tumor, osteasarcoma, neuroblastoma, leukemia and lymphoma (Ashkenazi et al., 1999; Walczak et al., 1999; LeBlanc and Ashkenazi, 2003) .
Also, TRAIL exhibited tumoricidal activity in vivo in several xenograft models of colon carcinoma, breast carcinoma, malignant glioma or multiple myeloma. Furthermore, monoclonal antibodies that engage the TRAIL receptors DR4 or DR5 also demonstrated potent antitumor activity against tumor cell lines and in preclinical cancer models (Chuntharapai et al., 2001; Ichikawa et al., 2001) .
Although these studies provided ample evidence of the potential of TRAIL for cancer therapy, many tumors remain refractory towards treatment with TRAIL, which has been related to the dominance of antiapoptotic signals. Importantly, numerous studies have shown that TRAIL synergized together with cytotoxic drugs or g-irradiation to achieve antitumor activity in various cancers including malignant glioma, Chinnaiyan et al., 2000; Keane et al., 2000; Nagane et al., 2000; Belka et al., 2001; Rohn et al., 2001) . Remarkably, TRAIL and anticancer agents also cooperated to suppress tumor growth in vivo in different murine models of human cancers. The molecular mechanisms that account for this synergistic interaction may include transcriptional upregulation of the agonistic TRAIL receptors TRAIL-R1 and TRAIL-R2, which occurred in a p53-dependent or -independent manner (Takimoto and El-Deiry, 2000; Meng and El-Deiry, 2001 ). Interestingly, p53 has also been shown to activate transcriptionally the antagonistic TRAIL decoy receptors TRAIL-R3 and TRAIL-R4 (Meng et al., 2000) . The synergistic interaction between cytotoxic drugs and TRAIL may also be mediated by the downregulation of antiapoptotic proteins such as Bcl-2, Bcl-X L or FLIP upon drug treatment (Olsson et al., 2001 ). In addition, anticancer agents may sensitize tumor cells for TRAIL treatment by upregulating proapoptotic molecules including caspases or FADD (Droin et al., 1998; Micheau et al., 1999) . Caspase-8 expression is frequently impaired by hypermethylation in several tumors including neuroblastoma, Ewing tumors, malignant brain tumors or lung carcinoma (Teitz et al., 2000; Fulda et al., 2001) . Importantly, restoration of caspase-8 expression by gene transfer or by demethylation treatment sensitized resistant tumor cells for TRAIL-induced apoptosis . Also, biological response modifiers such as IFNg strongly enhanced the cytotoxic activity of TRAIL by upregulating caspase-8 expression in a STAT-1-dependent manner (Srinivasula et al., 1999) . Since TRAIL demonstrated synergistic interaction with anticancer agents or irradiation, TRAIL may be most effective in combination with conventional cancer treatments. In addition, small molecules may serve as molecular therapeutics to target specifically tumor cell resistance toward TRAIL in resistant forms of cancer. To this end, Smac agonists including cell permeable peptides have recently been reported to potentiate the efficacy of TRAIL treatment by antagonizing the inhibitory effect of IAPs, which are overexpressed in many tumors (Tamm et al., 2000; Arnt et al., 2002; Fulda et al., 2002; Guo et al., 2002; Yang et al., 2003) . Importantly, Smac peptides synergized with TRAIL to eradicate malignant glioma in an orthotopic mouse model without any detectable toxicities to the normal brain tissue .
Most studies investigating TRAIL sensitivity of tumor cells have so far been performed in vitro using cell lines (Wajant et al., 2002) . However, experiments performed on primary cancer cells ex vivo yielded similar results and combined treatment of primary cancer cells with TRAIL together with anticancer agents also synergized in antitumor activity.
Targeting Bcl-2
Increased Bcl-2 expression has been experimentally associated with resistance to apoptosis induction by a wide variety of different stimuli including cytotoxic drugs but also by death receptor engangement at least in some cell types (Reed, 1997) . Antisense approaches targeting Bcl-2 by, for example, G3139 (Genasense), an antisense phosphothiorate oligonucleotide that suppresses Bcl-2 expression have been evaluated experimentally and also in clinical studies. Bcl-2 antisense therapy is well tolerated and preclinical studies have also shown that G313 may increase the anticancer effect of several cytotoxic drugs (Cotter et al., 1994; Webb et al., 1997; Ziegler et al., 1997; Waters et al., 2000; Banerjee, 2001; Chi et al., 2001; Morris et al., 2002; Olie et al., 2002; Rudin et al., 2002; Marcucci et al., 2003) . After completion of the phase I study in patients with nonHodgkin's lymphoma, partial response rates and stable disease have been reported in 14 or 43% of the patients, respectively (Waters et al., 2000) . Given the assumed implication of high Bcl-2 expression for treatment resistance, several preclinical studies and clinical trials are currently ongoing in leukemia, multiple myeloma, melanoma, lung cancer and prostate cancer (Chi et al., 2001; Morris et al., 2002; Olie et al., 2002; Rudin et al., 2002; Marcucci et al., 2003) .
Targeting IAPs
The IAP family of caspase inhibitors predominantly XIAP and survivin acting as downstream inhibitors of death receptor pathways have been shown to be highly expressed in various tumors including neuroblastoma, melanoma, breast cancer, non-small-cell lung tumors, gastrointestinal cancer and leukemia, suggesting a key role of this proteins in preventing cell death in cancer cells (Altieri, 2001; Salvesen and Duckett, 2002) . Thus, pharmacological intervention with IAP expression has received considerable scientific interest to resensitize tumor cells for apoptosis signals (Kanwar et al., 2001; Tamm et al., 2000; Xia et al., 2002; Altieri, 2003a, b; Tamm et al., 2003) . Downregulation of IAP proteins by antisense strategies has shown to increase sensitivity for death receptor stimulation. Also, the two negative regulators of IAP binding to caspases, SMAC/DIABLO and Omi, both localized in mitochondria, have been exploited for a possible therapeutic role in counteracting IAP-mediated inhibition of caspase activation. Along this line, SMAC agonists including cell permeable SMAC peptides have been generated and found to strongly sensitize previously resistant tumor cells for death receptor engagement by TRAIL and also cytotoxic drug treatment Tamm et al., 2003; Yang et al., 2003) . It is expected that small molecule SMAC agonists will be developed and evaluated in preclinical and clinical trails in the near future.
Conclusions
Numerous reports over the last years have provided evidence that anticancer therapies primarily act by triggering apoptosis in cancer cells. Key elements of the basic apoptosis machinery including signaling through death receptors or mitochondria have been implied to play a critical role in the surveillance of tumor formation as well as in cancer therapy. In addition, studies on the regulation of apoptosis signaling pathways upon cancer therapy have provided a substantial insight into the molecular mechanisms regulating the response of cancer cells towards current treatment regimens. Accordingly, defects in apoptosis programs may result in tumor cell resistance, and restoration of apoptosis sensitivity may be required for effective treatment. However, the concept that apoptosis represents the major mechanism by which cancer cells are eliminated may not universally apply, and caspaseindependent apoptosis or other modes of cell death also have to be considered. Also, detailed studies of apoptosis signaling molecules multiparameter settings in clinical samples are far from being complete and functional studies on the role of apoptosis molecules in individual tumors both in vitro and in vivo in tumor cells of patients under chemotherapy are clearly warranted. These studies may bridge the present gap between in vitro studies using cell lines and in vivo mouse models on one side and the clinical situation in the patient on the other side. Functional approaches will hopefully allow the identification of crucial targets for therapeutic intervention and may provide a basis for a more 'tailored' tumor therapy.
